Pegfilgrastim stands as a cornerstone long-acting granulocyte colony-stimulating factor (G-CSF) in global oncology care, specifically formulated to reduce the risk of chemotherapy-induced neutropenia (CIN) in non-malignant cancer treatments. As a high-demand biologic drug with critical patient safety implications, the global pegfilgrastim market features a structured network of institutional, pharmaceutical, and regional buyers focused on sourcing authentic originator and FDA/EMA-approved biosimilar variants. This comprehensive pegfilgrastim global buyers list outlines verified purchasing entities, core buyer categories, regional procurement trends, and key criteria for reliable cross-border pegfilgrastim sourcing, tailored for pharmaceutical suppliers, distributors, and industry stakeholders. Unlike generic pharmaceutical products, pegfilgrastim procurement requires strict regulatory compliance, cold-chain logistics certification, and validated supply chain…